



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/445,054	03/27/2000	NEAL ROSEN	696-US	9414

7590 03/02/2005
ALBERT WAI-KIT CHAN
WORLD PLAZA SUITE 604
141-07 20TH AVENUE
WHITESTONE, NY 11357

EXAMINER


COOK, REBECCA

ART UNIT	PAPER NUMBER
----------	--------------

1614

DATE MAILED: 03/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



**Supplemental
Notice of Allowability**

Application No.

09/445,054

Applicant(s)

ROSEN ET AL.

Examiner

Rebecca Cook

Art Unit

1614

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☐ This communication is responsive to _____.
2. ☐ The allowed claim(s) is/are _____.
3. ☐ The drawings filed on _____ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 - a) ☐ All b) ☐ Some* c) ☐ None of the:
 1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.
THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
 - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
 - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
 - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☒ Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date 8/7/01
4. ☐ Examiner's Comment Regarding Requirement for Deposit
of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☐ Interview Summary (PTO-413),
Paper No./Mail Date _____
7. ☐ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other _____



REBECCA COOK
PRIMARY EXAMINER

GROUP 1200 1614

STATEMENT BY APPLICANT

(use as many sheets as necessary)

APPLICANT
 AUG 07 2001
 (as necessary)
 PATENT & TRADEMARK OFFICE
 of

Sheet

1

1.0

of ~~AGENT & TRANSFER~~

Application Number

09/445.054

Filing Date

December 1, 1999

First Named Inventor

N. Rosen, et. al.

Group Art Unit

Examiner Name

Attorney Docket Number

19962YP

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number			
X	EP	0 856 315 A1			Banyu Pharmaceutical Co., LTD.	02/20/1997
X	EP	0 618 221 A2			Bristol-Myers Squibb Company	05/10/1994
Y	EP	0 670 314 A1			Kyowa Hakko Kogyo Co., LTD.	03/30/1995
X	PCT	WO 97/17070			University of Pittsburgh	05/15/1997
Y	EP	0 456 180 A1			E. R. Squibb & Sons, Inc.	11/13/1991
Y	PCT	WO 97/01275			Banyu Pharmaceutical Co., LTD.	01/16/1997
X	no	copies				

**Examiner
Signature**

Date Considered

10/4/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered.

Please type a plus sign (+) inside this box

SUBSTITUTED

Approved for use through 10/31/99. OMB 0651-0031
XOR (10/99). Information Disclosure Statement by Applicant
A Trademark Office, U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

2

of

Application Number

09/445,054

Filing Date

December 1, 1999

First Named Inventor

N. Rosen, et. al.

Group Art Unit

Examiner Name

Attorney Docket Number

19962YP

OTHER NON PATENT LITERATURE DOCUMENTS

**Examiner
Initials***

**Cite
No.**

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Moasser, et al., Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones, February 1998, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1369-1374 Molecular Pharmacology, Vol. 47, pp. 1106-1111 (1995)

1 Danesi, Paclitaxel (Taxol) Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human Prostate
Cancer Cells, 1995, Molecular Pharmacology, Vol 47, pp. 1106-1111

✓ no copies

**Examiner
Signature**

Date Considered

10/5/01

*Examiner. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



RECEIVED

00 JUN -2 AM 11:54

JUN 07 2000
 SUSAN GALLAGHER
 Merck & Co., Inc.
 PATENT DEPARTMENT
 P.O. Box 2000
 Rahway, New Jersey 07065 - 0907

006409300
 006409300

P&T OFFICE ACKNOWLEDGEMENT

ATTORNEY		DATE
David A. Mithani		5/24/00
CASE NUMBER	SERIAL NUMBER	
19962YP	09/411,054	
DATE FILED	APPLICANT	
12/1/99	N. Rosen, et al.	
EXPRESS MAIL NO.		

The Patent & Trademark Office acknowledges and has stamped hereon, the date of the receipt of the items checked below:

- ☐ AMENDMENT
- ☐ APPEAL AND FEE
- ☐ ASSIGNMENT
- ☐ BRIEF
- ☐ CERTIFICATE OF CORRECTION
- ☐ FINAL FEE
- ☐ LETTER
- ☐ REQUEST FOR F.F. LICENSE
- ☒ INFORMATION DISCLOSURE STATEMENT
- ☒ PTO 1449 & REFERENCES (10 References)
- ☐ PETITION FOR EXTENSION OF TIME & FEE
- ☐ INVITATION TO CORRECT
- ☐ DEMAND-CHAPTER II & FEE SHEET

F4424

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: N. Rosen

Serial No. 09/445,054

Filed: December 1, 1999

For: A METHOD OF TREATING CANCER

Art Unit: _____

Examiner: _____

Assistant Commissioner for Patents
Washington, D.C. 20231

DOCKETED

MAY 24 2000

BARBARA REILLY

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97

Sir:

1. In compliance with 37 C.F.R. 1.97, submitted on the attached form herewith is a list of patents, publications or other information which are requested to be made of record in this application.

This Information Disclosure Statement is not an admission that any patent, publication or other information referred to herein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. 1.56(b).

2. In accordance with 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made.

3. Applicants respectfully request that the Examiner initial the attached form after reviewing the pertinence of each reference.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date appearing below.

MERCK & CO., INC.

By _____

Date

5/24/00

— INFORMATION DISCLOSURE STATEMENT

4. Copies of the references listed on the attached form are not enclosed because they have been submitted to or cited by the Office in a related application as follows:


U. S. SERIAL NUMBER	RELATED APPLICATION	
	FILING DATE	MERCK CASE
		19962

upon which the instant application relies for an earlier filing date under 35 U.S.C. 120. Therefore, pursuant to 37 C.F.R. 1.98(d), copies of these references are not enclosed herewith. If this is inconvenient, additional copies will be submitted upon request.

5. In accordance with 37 C.F.R. 1.97, (check one)

- ☐ the attached information is filed within three months of the filing date of the captioned case.
- ☒ the attached information is filed more than three months after the filing date but prior to a first Official Action on the merits.
- ☐ the attached information is being filed more than three months after the filing date and after receipt of the first Office Action on the merits, but before Final Action or Notice of Allowance. The enclosed authorization is therefore given to charge Deposit Account No. 13-2755 for the fee required under 37 C.F.R. 1.17(p).
- ☐ the undersigned certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement.
- ☐ the undersigned certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated under 37 C.F.R. 1.56(c) more than three months prior to the filing of the statement.

Respectfully submitted,

By:  David A. Muthard

Attorney _____ For Applicant(s)

Reg. No. 35,297

MERCK & CO., INC.

Patent Dept., RY60-30

P.O. Box 2000

Rahway, N.J. 07065-0907

(732)594- 3903

Date: May 24, 2000

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/445,054
---------------------------	------------

Filing Date	December 1, 1999
--------------------	------------------

First Named Inventor	N. Rosen, et. al.
-----------------------------	-------------------

Group Art Unit

Examiner Name

Attorney Docket Number	19962YP
------------------------	---------

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)		
		EP	0 856 315 A1		Banyu Phameceutical Co., LTD.	02/20/1997
		EP	0 618 221 A2		Bristol-Myers Squibb Company	05/10/1994
		EP	0 670 314 A1		Kyowa Hakko Kogyo Co., LTD.	03/30/1995
		PCT	WO 97/17070		University of Pittsburgh	05/15/1997
		EP	0 456 180 A1		E. R. Squibb & Sons, Inc.	11/13/1991
		PCT	WO 97/01275		Banyu Phameceutical Co., LTD.	01/16/1997

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(use as many sheets as necessary)

COMPLETE IF KNOWN

Application Number	09/445,054
---------------------------	------------

Filing Date	December 1, 1999
--------------------	------------------

First Named Inventor	N. Rosen, et. al.
-----------------------------	-------------------

Group Art Unit

Examiner Name

Attorney Docket Number 19962YP

Sheet

2

of

2

OTHER NON PATENT LITERATURE DOCUMENTS

Examiner
Initials*Cite
No.

Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.

Moasser, et al., Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones, February 1998, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1369-1374 Molecular Pharmacology, Vol. 47, pp. 1106-1111 (1995)

Danesi, Paclitaxel (Taxol) Inhibits Protein Isoprenylation and Induces Apoptosis in PC-3 Human Prostate Cancer Cells, 1995, *Molecular Pharmacology*, Vol 47, pp. 1106-1111

**Examiner
Signature**

Date Considered

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Europäisches Patentamt
European Patent Office
Office européen des brevets



Publication number: **0 456 180 A1**

12

EUROPEAN PATENT APPLICATION

21 Application number: 91107390.6

51 Int. Cl.⁵: C12N 9/10, C12Q 1/48

22 Date of filing: 07.05.91

30 Priority: 08.05.90 US 520570

43 Date of publication of application:
13.11.91 Bulletin 91/46

64 Designated Contracting States:
DE FR GB IT

71 Applicant: E.R. SQUIBB & SONS, INC.
P.O.Box 4000
Princeton New Jersey 08543-4000(US)

72 Inventor: Barbacid, Mariano
5 Stony Creek Place
Lawrenceville, NJ(US)
Inventor: Manne, Veeraswamy
9926 Haldemann Ave. No. 35a
Philadelphia, PA(US)

74 Representative: Vossius & Partner
Siebertstrasse 4 P.O. Box 86 07 67
W-8000 München 86(DE)

54 Farnesyl-protein transferase assay for identifying compounds that block neoplastic transformation.

57 Assays for farnesyl-protein transferase (FT) which can be used to identify substances that block the farnesylation of ras oncogene products are described. Because farnesylation is required for ras oncogene activity, inhibitory compounds identified in the assays of the invention can block neoplastic transformation mediated by the ras oncogene. The assays of the invention are targeted for a step subsequent to the synthesis of farnesyl pyrophosphate (FPP), the donor of the farnesyl residue, and an intermediate in cholesterol synthesis and other important cellular pathways. Therefore, compounds which inhibit ras mediated transformation, yet do not cause major disruptions of important cell pathways that require FPP as an intermediate may be identified using the assays of the invention.

EP 0 456 180 A1